Hospitals approve Osteotechs Plexur M bone-polymer biocomposite Osteotech.
‘Since the arrival of the controlled discharge in the U.S., Plexur M provides been used in a range of surgical treatments and is building a reputation mainly because a go-to biologic for orthopedic surgeries requiring tailored solutions,’ said Sam Owusu-Akyaw, Osteotech’s President and Chief Executive Officer. ‘As we’ve continued to communicate the differentiating advantages that Plexur M presents, we have obtained mindshare among orthopedic surgeons focused on orthopedic trauma, joint replacements, and oncology-related methods.Today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical elements, . The collaboration combines Saneca's strength in extracting opiates from plant biomass and their expertise in developing and manufacturing controlled compound APIs with AMRI's U.S. Resources and their capability to tech transfer processes into these services. The collaboration may also capitalize on AMRI's marketing and sales power in the U.S. Market. Under conditions of the collaboration, Saneca will supply intermediates, and where appropriate, procedure transfer technology to enable AMRI to develop over two dozen APIs.